Young T cells age during a redirected anti-tumor attack: Chimeric antigen receptor-provided dual costimulation is half the battle

10Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Adoptive therapy with chimeric antigen receptor (CAR)-redirected T cells showed spectacular efficacy in the treatment of leukemia in recent early phase trials. Patient's T cells were ex vivo genetically engineered with a CAR, amplified and re-administered to the patient. While T cells mediating the primary response were predominantly of young effector and central memory phenotype, repetitive antigen engagement irreversible triggers T cell maturation leaving late memory cells with the KLRG1+ CD57+ CD7- CCR7- phenotype in the long-term. These cells preferentially accumulate in the periphery, are hypo-responsive upon TCR engagement and prone to activation-induced cell death. A recent report indicates that those T cells can be rescued by CAR provided CD28 and OX40 (CD134) stimulation. We discuss the strategy with respect to prolong the anti-tumor response and to improve the over-all efficacy of adoptive cell therapy. © 2013 Hombach and Abken.

Cite

CITATION STYLE

APA

Hombach, A. A., & Abken, H. (2013). Young T cells age during a redirected anti-tumor attack: Chimeric antigen receptor-provided dual costimulation is half the battle. Frontiers in Immunology, 4(JUN). https://doi.org/10.3389/fimmu.2013.00135

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free